- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Safety and Efficacy of HER2-Directed ADCs for NSCLC
Panelists discuss how the selection between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine is guided by findings from pivotal trials like DESTINY-Lung01 and DESTINY-Lung02, real-world patient outcomes compared with clinical trial results, and the management of common treatment-related adverse events associated with these HER2-directed therapies.
EP: 1.Introduction and Current Landscape of HER2 in NSCLC
EP: 2.Safety and Efficacy of HER2-Directed ADCs for NSCLC
EP: 3.Treatment Considerations for Patients With HER2+ NSCLC
EP: 4.Latest Advances and Therapies for HER2+ NSCLC
EP: 5.Unmet Needs and Clinical Considerations for HER2+ NSCLC
EP: 6.Integrating HER2-Directed Therapies Into Standard Care for NSCLC
EP: 7.HER2- Mutation Testing Considerations and Timing
EP: 8.Factors Impacting Use of HER2 Therapies for NSCLC
EP: 9.Incorporating Real-World Evidence for HER2+ NSCLC
EP: 10.Key Takeaways on the Future of HER2 in NSCLC
EP: 11.Real-World Outcomes in HER2-Positive NSCLC
EP: 12.Managing Treatment Challenges in HER2-Directed Therapies
EP: 13.Emerging Horizons in HER2-Directed NSCLC Treatments
EP: 14.Patient Selection and Personalized Treatment Strategies
EP: 15.Navigating Healthcare Access and Decision-Making
Video content above is prompted by the following:
- What factors guide the choice between fam-trastuzumab deruxtecan-nxki and ado-trastuzumab emtansine?
- What key insights emerged from pivotal trials like the phase 2 basket DESTINY-Lung01and DESTINY-Lung02?
- How do real-world patient outcomes compare with those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Historical Redlining Increases Mortality Risk Among Young Patients With Cancer
January 27th 2025Young patients with cancer residing in historically redlined areas face a significantly higher risk of mortality, demonstrating that structural racism contributes to disparities in survival outcomes.
Read More
FDA Approves New Maintenance Dosing for Lecanemab to Treat Early-Stage Alzheimer Disease
January 27th 2025The FDA approves a new maintenance dosing regimen for lecanemab (Leqembi; Eisai) in patients with early-stage Alzheimer disease (AD), enabling a transition from biweekly to once-every-4-week dosing while preserving clinical and biomarker benefits.
Read More
